journal
MENU ▼
Read by QxMD icon Read
search

Expert Review of Molecular Diagnostics

journal
https://www.readbyqxmd.com/read/30513018/assay-challenges-and-opportunities-with-non-factor-viii-therapies-for-hemophilia-a
#1
Maria M Aleman, Nina C Leksa, Robert Peters, Joe Salas
No abstract text is available yet for this article.
December 4, 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/30513011/label-free-plasmonic-biosensors-for-point-of-care-diagnostics-a-review
#2
Maria Soler, Cesar S Huertas, Laura M Lechuga
Optical biosensors and particularly those based on nanoplasmonics technology have emerged in recent decades as a potential solution for disease diagnostics and therapy follow-up at the point-of-care. These biosensor platforms could overcome some of the challenges faced in conventional diagnosis techniques offering label-free assays with immediate results and employing small and user-friendly devices. Areas covered: In this review, we will provide a critical overview of the recent advances in the development of nanoplasmonic biosensors for point-of-care diagnostics...
December 4, 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/30513010/plasma-dna-for-early-cancer-detection-opportunities-and-challenges
#3
W K Jacky Lam, K C Allen Chan
No abstract text is available yet for this article.
December 4, 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/30452305/upper-urinary-tract-urothelial-carcinoma-and-its-variants-transition-from-morphology-to-personalized-molecular-characterization-in-diagnosis-prognosis-and-therapy
#4
Alessia Cimadamore, Marina Scarpelli, Matteo Santoni, Liang Cheng, Antonio Lopez-Beltran, Rodolfo Montironi
Upper tract urothelial carcinoma (UTUC) accounts for 5% of urothelial carcinomas (UCs), the estimated annual incidence being 1-2 cases per 100,000 inhabitants. The aim of this review was to summarize the main morphologic features of UTUC as well as the current status and future role of its molecular characterization in diagnosis, prognosis, and therapy. Areas covered: Several studies on the UTUCs have shown the diagnostic, prognostic, and therapeutic significance of standard pathological features, such as tumor stage, grade, and lymph node metastasis...
November 19, 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/30427756/the-clinical-use-of-idh1-and-idh2-mutations-in-gliomas
#5
Alberto Picca, Giulia Berzero, Anna Luisa Di Stefano, Marc Sanson
Mutations in the genes isocitrate dehydrogenase (IDH) 1 and 2 have been reported in a limited number of tumors. In gliomas, IDH mutations are primarily detected in WHO grade II-III tumors and represent a major biomarker with diagnostic, prognostic, and predictive implications. The recent development of IDH inhibitors and vaccines suggests that the IDH mutation is also an appealing target for therapy. Areas covered: This review focuses on the role of IDH mutations in diffuse gliomas. Besides discussing their role in gliomagenesis, we will emphasize the role of IDH mutations in clinical practice as a diagnostic, prognostic and predictive biomarker, and as a potential therapeutic target...
November 14, 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/30413130/an-updated-view-on-the-origin-and-use-of-angiogenic-biomarkers-for-preeclampsia
#6
Berthold Huppertz
The last decade has seen massive efforts towards the identification and the potential use of predictive biomarkers for the pregnancy pathology preeclampsia. The angiogenic factors sFlt-1 and placental growth factor (PGF) have been in focus and have been massively supported. Areas covered: This review describes preeclampsia and intra-uterine growth restriction (IUGR), focusing on sFlt-1 and PGF, their sources during and outside pregnancy and the application of these markers in diseases outside pregnancy. Finally, the specificity of the angiogenic markers for preeclampsia is discussed...
November 9, 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/30411633/tumor-specific-methylations-in-circulating-cell-free-dna-as-clinically-applicable-markers-with-potential-to-substitute-mutational-analyses
#7
Rikke Fredslund Andersen
Analysis of circulating tumor DNA is a promising approach to guide the treatment of cancer patients but despite large efforts it has not been broadly applied in the clinic. Technical obstacles and lack of standardization have hampered the process and it has proved challenging to make highly sensitive analyses available for all patients. Research has focused on the use of somatic mutations but because of large mutational diversity among patients the setup becomes unmanageable for daily routine use. Areas covered: Methylations are key events in cancer development and can be used as markers for the presence of circulating tumor DNA similar to how mutations have been used...
November 9, 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/30406709/the-potential-of-tumor-derived-exosomes-for-noninvasive-cancer-monitoring-an-update
#8
Theresa L Whiteside
Liquid biopsy platforms are being actively developed in the biomarker field. Extracellular vesicles (EVs), especially the tumor-derived exosome (TEX) subsets of EVs, represent a platform that allows for molecular and genetic profiling of parent tumor cells. TEX are ubiquitous in body fluids of cancer patients and are promising clinically relevant surrogates of cancer cells. Areas covered: Isolation from body fluids of cancer patients and subsetting of exosomes based on immunoaffinity capture offers a means of evaluating proteins, lipids, nucleic acids and other molecular contents that are a characteristic of TEX and exosomes produced by reprogrammed normal cells...
November 8, 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/30394810/reproductive-autonomy-in-expanded-carrier-screening-more-than-meets-the-eye
#9
Davit Chokoshvili, Danya F Vears, Pascal Borry
No abstract text is available yet for this article.
November 5, 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/30392417/the-microbiome-of-pancreatic-cancer-from-molecular-diagnostics-to-new-therapeutic-approaches-to-overcome-chemoresistance-caused-by-metabolic-inactivation-of-gemcitabine
#10
Arthur T F Choy, Ilaria Carnevale, Stefano Coppola, Laura L Meijer, Geert Kazemier, Egija Zaura, Dongmei Deng, Elisa Giovannetti
Pancreatic cancer is a complex disease, with an extremely poor response to chemotherapy. Emerging evidence indicates that the tumor microenvironment (TME) might play an important role in mediating chemoresistance. Areas covered: The evaluated study by Geller and collaborators describes several bacterial species within pancreatic tumor tissues and TME and investigated their roles in gemcitabine chemoresistance. Intratumor bacteria express the enzyme cytidine deaminase (CDD), whose long form (CDDL ) was shown to metabolize gemcitabine into its inactive metabolite...
November 5, 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/30381977/pcr-detection-of-mycobacterium-ulcerans-significance-for-clinical-practice-and-epidemiology
#11
Gisela Bretzel, Marcus Beissner
Buruli ulcer (BU) is a neglected disease which has been reported from mostly impoverished, remote rural areas from 35 countries worldwide. BU affects skin, subcutaneous tissue and bones, and may cause massive tissue destruction and life-long disabilities if not diagnosed and treated early. Without laboratory confirmation diagnostic and treatment errors may occur. This review describes the application of IS2404 PCR, the preferred diagnostic test, in the area of individual patient management and clinico-epidemiological studies...
November 1, 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/30372355/profile-of-the-versant-hcv-genotype-2-0-assay
#12
Ruifeng Yang, Lai Wei
Hepatitis C virus (HCV) is divided into 7 genotypes and 67 subtypes. HCV genotype studies reflect the viral transmission patterns as well as human migration routes. In a clinical setting, HCV genotype is a baseline predictor for the sustained virological response (SVR) in chronic hepatitis C patients treated with peginterferon or some direct acting antivirals (DAAs). The Versant HCV genotype 2.0 assay has been globally used for HCV genotyping over a decade. Areas covered: The assay is based on reverse hybridization principle...
October 29, 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/30345836/biomarkers-for-barrett-s-esophagus-a-contemporary-review
#13
Alia P Qureshi, Matthew D Stachler, Omar Haque, Robert D Odze
Esophageal adenocarcinoma (EAC) has a poor 5-year survival rate (10%-18%), and incidence has increased dramatically in the past three decades. Barrett's esophagus (BE) is the precursor lesion to EAC and is the replacement of the normally squamous lined esophagus with columnar cells that develop an intestinal phenotype characterized by the presence of goblet cells. Given the known precursor state, EAC is amenable to screening and surveillance strategies (analogous to colon cancer). However, unlike from colon cancer screening, BE poses challenges that make effective screening difficult...
November 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/30345829/clinical-utility-of-micrornas-in-renal-cell-carcinoma-current-evidence-and-future-perspectives
#14
Panagiotis Tsiakanikas, Constantinos Giaginis, Christos K Kontos, Andreas Scorilas
MicroRNAs (miRNAs) are small, non-coding RNA molecules that epigenetically regulate gene expression. Recently, it has been shown that miRNAs are heavily involved in renal carcinogenesis by controlling the expression of proteins related to renal cell carcinoma (RCC) and, thus, the activity of key signaling pathways involved in pivotal cell processes. Areas covered: This review focuses on the role of miRNAs as emerging biomarkers in RCC. We summarize the oncogenic and/or tumor-suppressive functions of miRNAs as well as the strong clinical information that these RNA molecules provide...
November 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/30338716/mirna-and-long-non-coding-rna-molecular-function-and-clinical-value-in-breast-and-ovarian-cancers
#15
Konstantina Panoutsopoulou, Margaritis Avgeris, Andreas Scorilas
The elucidation of tumor molecular hallmarks and the identification of novel molecular markers are of first translational priority in breast and ovarian cancer research, aiming to support personalized disease treatment and monitoring decisions. Recent high-throughput studies have revealed that ~ 80% of the genome is transcribed into RNAs without protein-coding potential, namely non-coding RNAs (ncRNAs), challenging the concept of 'junk DNA'. Undoubtedly, microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) represent the best-studied family classes, emerging as the most powerful gene-expression regulators at epigenetic, transcriptional and post-transcriptional levels...
November 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/30324828/genetic-testing-for-high-grade-osteosarcoma-a-guide-for-future-tailored-treatments
#16
Claudia Maria Hattinger, Maria Pia Patrizio, Elisa Tavanti, Silvia Luppi, Federica Magagnoli, Piero Picci, Massimo Serra
Genetic characterization of osteosarcoma has evolved during the last decade, thanks to the integrated application of conventional and new candidate-driven and genome-wide technologies. Areas covered: This review provides an overview of the state of art in genetic testing applied to osteosarcoma, with particular regard to novel candidate genetic biomarkers that can be analyzed in tumor tissue and blood samples, which might be used to predict toxicity and prognosis, detect disease relapse, and improve patients' selection criteria for tailoring treatment...
November 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/30307788/we-have-the-technology-but-should-we-build-the-test
#17
Barbara Van Der Pol
No abstract text is available yet for this article.
November 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/30307786/prognostic-utility-of-circulating-nucleic-acids-in-acute-brain-injuries
#18
Andrea Regner, Lindolfo da Silva Meirelles, Nilo Ikuta, Andre Cecchini, Daniel Simon
Acute brain injuries represent major causes of morbidity and mortality worldwide. Nevertheless, therapeutic options are centered mainly on supportive care, and accurate prognosis prediction following traumatic brain injury (TBI) or stroke remains a challenge in clinical settings. Areas covered: Circulating DNA and RNA have shown potential as predictive molecules in acute brain injuries. In particular, plasma cell-free DNA (cfDNA) levels have been correlated to severity, mortality, and outcome after TBI and stroke...
November 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/30289289/biomarkers-for-acute-radiation-syndrome-challenges-for-developing-radiation-countermeasures-following-animal-rule
#19
Vijay K Singh, Madison Simas, Harvey Pollard
No abstract text is available yet for this article.
November 2018: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/30222014/recent-advances-in-molecular-testing-to-improve-early-diagnosis-in-children-with-mucopolysaccharidoses
#20
Ana Carolina Brusius-Facchin, Diana Rojas Malaga, Sandra Leistner-Segal, Roberto Giugliani
The mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders with high phenotypic and genotypic heterogeneity, making precise diagnosis challenging. Although enzyme activity assay is considered the gold standard for the diagnosis of these disorders, molecular testing can greatly refine this task. New methods for rapid detection of variants are useful to reduce the 'diagnostic odyssey' faced by patients and their family, to lead to appropriate genetic counseling and to select the most appropriate therapy for each case...
October 2018: Expert Review of Molecular Diagnostics
journal
journal
39742
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"